
-
Liverpool boss Slot fears replacing Alexander-Arnold will be a tough task
-
British Airways owner unveils big Boeing, Airbus order
-
IPL suspended for one week over India-Pakistan conflict
-
Slot says all at Liverpool sad to see Alexander-Arnold go
-
Leo XIV celebrates first mass as pope in Sistine Chapel
-
India says repulsed fresh Pakistan attacks as death toll climbs
-
Japan's Panasonic targets 10,000 job cuts worldwide
-
Putin evokes WWII victory to rally Russia behind Ukraine offensive
-
China exports beat forecasts ahead of US tariff talks
-
Leo XIV, the 'Latin Yankee', to celebrate first mass as pope
-
Most stocks lifted by hopes for US-China talks after UK deal
-
IPL suspended indefinitely over India-Pakistan conflict: reports
-
German lender Commerzbank's profits jump as it fends off UniCredit
-
Rare bone-eroding disease ruining lives in Kenya's poorest county
-
India says repulsed fresh Pakistan attacks as de-escalation efforts grow
-
Zhao's historic snooker title sparks talk of China world domination
-
'High expectations': EU looks to Merz for boost in tough times
-
Poisoned guests rarely invited before deadly mushroom lunch, Australia trial hears
-
China sales to US slump even as exports beat forecasts
-
Indian cricket to make 'final decision' on IPL over Pakistan conflict
-
Dethroned Bundesliga champions Leverkusen face uncertain future
-
China can play hardball at looming trade talks with US: analysts
-
French monuments in trouble while PSG prepare for Champions League final
-
Newcastle face Chelsea in top five showdown, Alexander-Arnold in spotlight
-
Flick's Barca must show 'hunger' in crunch Liga Clasico
-
Clasico the last chance saloon for Ancelotti's Real Madrid
-
Timberwolves overpower Warriors to level series
-
Chinese fabric exporters anxious for US trade patch-up
-
Putin gears up to host world leaders at lavish army parade
-
Nearing 100, Malaysian ex-PM Mahathir blasts 'old world' Trump
-
Leo XIV, first US pope, to celebrate first mass as pontiff
-
Asian stocks lifted by hopes for US-China talks after UK deal
-
Former head of crypto platform Celsius sentenced 12 years
-
Ex-model testifies in NY court that Weinstein assaulted her at 16
-
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
-
Ascendant Resources Announces Closing of Second and Final Tranche of Non-Brokered Private Placement
-
Nestlé and OMP Showcase Approach to Future-Ready Supply Chain at Gartner Supply Chain Symposium/Xpo in Barcelona
-
Genflow Biosciences PLC Announces Share Subscription, Director's Dealing and Update
-
Argo Blockchain PLC Announces 2024 Annual Results and Restoration of Listing
-
'Great honor': world leaders welcome first US pope
-
Pacquiao to un-retire and fight Barrios for welterweight title: report
-
Trump unveils UK trade deal, first since tariff blitz
-
Man Utd one step away from Europa League glory despite horror season
-
Jeeno shines on greens to grab LPGA lead at Liberty National
-
Mitchell fires PGA career-low 61 to grab Truist lead
-
AI tool uses selfies to predict biological age and cancer survival
-
Extremely online new pope unafraid to talk politics
-
Postecoglou hits back as Spurs reach Europa League final
-
Chelsea ease into Conference League final against Betis
-
Pope Leo XIV: Soft-spoken American spent decades amid poor in Peru

First post-Covid jab claims land in German courts
German courts will from Monday begin examining a series of claims over adverse effects suffered after coronavirus vaccinations, more than two years after one of the world's fastest and most extensive innoculation campaigns.
In the face of a deadly pandemic that emerged in early 2020, which prompted border closures and lockdowns that trapped millions of people in their homes, the arrival of Covid vaccines had been widely hailed as a life-saver.
But the jabs, which had been developed at breakneck speed and granted early approval for usage, are now the focus of legal claims in several countries including France and Britain as the plaintiffs say the vaccines damaged their health.
In Germany, a court in Hamburg will be the first to hear a case brought against homegrown vaccine manufacturer BioNTech, which, together with US giant Pfizer, produced the first mRNA vaccine Comirnaty.
The claimant reported suffering effects including "pain in the upper body, swelling of the extremities, exhaustion, fatigue and sleeping disorders" after taking the jab, the court said.
She is seeking 150,000 euros ($162,000) in damages and recognition that the "defendant is bound to provide material damages", the court added.
Her lawyer Thomas Ulbrich, who is also representing another 250 people in similar cases, said his clients were "all healthy" before suffering from symptoms, allegedly following their jabs.
He believes that the medical files he has on hand offer a link between the vaccines and the symptoms experienced by his clients.
- 'Rocky and long road' -
BioNTech's mRNA vaccine, a scientific breakthrough, had been granted conditional marketing authorisation as early as December 21, 2020, by the EU regulatory authority EMA.
Similar authorisation for Moderna, another mRNA vaccine maker, swiftly followed.
With fears of catching the disease running high, the vaccines were pre-ordered by governments even during their development phases, and deployment swiftly followed once regulatory authorities gave their approval.
But the new generation of inoculations also sparked a wave of vaccine sceptics questioning the safety of the jabs.
Out of 192 million jabs given in Germany, the country's medecines regulator, the Paul Ehrlich Institute, said 338,857 suspected cases of side effects were reported, including 54,879 severe reactions.
Among the worst cases, "the symptoms are very different, they vary from stroke to thrombosis to cardiac diseases", said another German lawyer, Joachim Caesar-Preller, who represents 140 clients making similar claims.
He is seeking up to one million euros in damages per case -- plus interest -- but concedes that a "rocky and long road" lies ahead in the legal battles.
- 'Not an isolated case' -
A key point for the courts is whether the side effects of the medication, when used correctly, surpass "a justifiable level according to the findings of medical science".
In other words, the effects have to be sufficiently serious to be taken into account, said Anatol Dutta, a professor at Munich University.
A claimant identified only as Kathrin K., 45, believes her symptoms are severe enough.
She said she lost a lot of weight after taking the vaccine and had to undergo several intestinal operations.
"I hate it when people tell me that I'm an isolated case," she said. "I'm not."
To address the question of causality, the courts would likely have to obtain expert advice.
Besides the legal avenue, claimants can also turn to the state for compensation for the loss of income.
More than 8,000 such applications had been made as of April, and so far about five percent have been successful, according to German media.
In a statement to AFP, BioNTech said that the number of liability claims made to the company is very small when compared to the number of doses it has delivered worldwide, and that each claim had to be examined individually.
"Justified liability claims would of course be met by BioNTech," it said, adding however that "no causal relationship between (the) health impairments presented and vaccination with Comirnaty has been proven" in the cases it had reviewed so far.
Another lawyer, Anja Dornhoff, advises her clients to establish a chronology and to get medical practitioners to document the development of their symptoms.
"I hope that people with post-vaccination syndromes can be taken seriously," she said.
S.Gregor--AMWN